Literature DB >> 10954628

Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.

F Millán-Rodríguez1, G Chéchile-Toniolo, J Salvador-Bayarri, J Palou, F Algaba, J Vicente-Rodríguez.   

Abstract

PURPOSE: We identified risk groups in primary superficial bladder cancer according to progression, mortality and recurrence rates.
MATERIALS AND METHODS: The prognostic factors of progression, mortality and recurrence were identified by multivariate analysis in a cohort of 1,529 patients with primary superficial bladder cancer. Risk groups were designed by combining the relative risk of these prognostic factors. We performed survival analysis of progression, tumor mortality and recurrence by risk group using the Kaplan-Meier method. Relative risk in each group was calculated by Cox regression. We present timetables of progression, mortality and recurrence by risk group.
RESULTS: Risk groups were classified as low-grade 1 stage Ta disease and a single grade 1 stage T1 tumor, intermediate-multiple grade 1 stage T1 tumors, grade 2 stage Ta disease and a single grade 2 stage T1 tumor, and high-multiple grade 2 stage T1 tumors, grade 3 stages Ta and T1 disease, and any stage disease associated with carcinoma in situ. Survival analysis of progression, mortality and recurrence revealed a statistically significant difference among the 3 risk groups. The rates of recurrence, progression and mortality were 37%, 0% and 0% in the low, 45%, 1.8% and 0.73% in the intermediate, and 54%, 15% and 9.5% in the high risk group, respectively. The relative risks of recurrence, progression and mortality in the low versus the intermediate and high risk groups were 1.37, 2.84 and 1, and 1.87, 24.76 and 14.69, respectively.
CONCLUSIONS: Risk group classification based on prognostic factors defines progression, mortality and recurrence rates in primary superficial bladder cancer. It may be useful for designing treatment and followup strategies.

Entities:  

Mesh:

Year:  2000        PMID: 10954628     DOI: 10.1016/s0022-5347(05)67280-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  96 in total

1.  Bladder cancer mortality in the Epirus district population (Greece).

Authors:  D Baltogiannis; A Tasos; G Voutsinas; H Dauaher; P Chambilomatis; X Giannakopoulos
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

Review 3.  Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.

Authors:  Ashish M Kamat; J Alfred Witjes; Maurizio Brausi; Mark Soloway; Donald Lamm; Raj Persad; Roger Buckley; Andreas Böhle; Marc Colombel; Joan Palou
Journal:  J Urol       Date:  2014-03-25       Impact factor: 7.450

4.  Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.

Authors:  A Quintero; J Alvarez-Kindelan; R J Luque; R Gonzalez-Campora; M J Requena; R Montironi; A Lopez-Beltran
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

5.  Early detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients.

Authors:  Salvatore Blanco; Marco Raber; Biagio Eugenio Leone; Luca Nespoli; Marco Grasso
Journal:  J Transl Med       Date:  2010-11-22       Impact factor: 5.531

6.  [Prediction of tumor recurrence and progression of superficial bladder carcinoma using an artificial neural network].

Authors:  B Planz; T Deix; H P Caspers
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

7.  Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.

Authors:  Gary H Lyman; Nicole M Kuderer; Stephen J Freedland
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

8.  Low-Grade, Multiple, Ta Non-muscle-Invasive Bladder Tumors: Tumor Recurrence and Worsening Progression.

Authors:  R B Nerli; Shridhar C Ghagane; K Shankar; Adarsh C Sanikop; Murigendra B Hiremath; Neeraj S Dixit; Laxman Magadum
Journal:  Indian J Surg Oncol       Date:  2018-01-29

9.  Long non-coding RNA HNF1A-AS1 promotes cell viability and migration in human bladder cancer.

Authors:  Zhihong Feng; Baolong Wang
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

Review 10.  Use of nomograms as predictive tools in bladder cancer.

Authors:  Ahmad Shabsigh; Bernard H Bochner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.